ACO REACH Model & WAHOO RSO Sample Exhibits

PRESENTED BY:

Michael Forster, ASA, MAAA michael.forster@wakely.com

Brad Heywood, ASA, MAAA brad.heywood@wakely.com



Contents

ACO REACH MODEL

DCE Risk Adj. Exhibit

RISKSCORE_AD

Provider Level

WAHOO RSO

PY2023 Opportunity from Recapture and Association

Scenario



ACO REACH



DCE Risk Adj. Exhibit

Sampl	e Direct Contracting RAF Calculation					Comments
Ref	DCE	DCE A	DCE B	DCE C	Total DCE Aligned	General comments: the risk model for standard assigned members is the CMS-HHC prospective risk model. The experience period is the 12 months immediately before the start of the performance period.
N (1)	Ref Yr. (RY) 2019 DCE Mean Risk Score	1.137	1.092	1.194	1.141	Assumed average risk scores for 3 DCEs. Assumptions:
o (1b)) RY 2021 DCE Mean Risk Score	1.184	1.168	1.177	1.176	DCEs all the same size and represent the entire DCE
m (2)	PY 2023 DCE Mean Risk Score	1.232	1.244	1.350	1.275	population for aligned members
a (3)	RY 2019 Norm Factor	1.137	1.137	1.137	1.137	National MA coding normalization factor developed by OACT
i (3b)) RY 2021 Norm Factor	1.099	1.099	1.099	1.099	to adjust aggregate risk score to 1.000 so that the HCC risk model does produce an average risk score of 1.000 and thus
z (4)	PY 2023 Norm Factor	1.184	1.184	1.184	1.080	does not produce higher revenue.
a (5)	RY 2019 DCE Mean Norm Risk Score (1) / (3)	1.000	0.960	1.050	1.004	Calculated as shown. Purpose is to adjust the risk scores using
i (5b)	RY 2021 DCE Mean Norm Risk Score (1b) / (3b)	1.078	1.063	1.071	1.070	the national normalization factors to put the DCE risk scores of
n (6)	PY 2023 DCE Mean Norm Risk Score (2) / (4)	1.040	1.051	1.140	1.077	the same basis as the HCC risk model.
C (7)	DCE Risk Growth Rate [(6)/(5b)] - 1	-3.46%	-1.15%	6.46%		The 3% cap is relative to the 2 year prior (or 2022 starting in
a p (8)	PY DCE Capped Mean Risk Score	1.110	1.095	1.103	1.103	2024) normalized risk score; Demographic Risk Score can increase or lower the 3% cap under ACO REACH
(8b)	PY DCE Risk Score after capping	1.045	1.051	1.103	1.066	
C (0)		4.052	4.050	4.053	4.050	The CIF is calculated in reference to RY 2019. It is a national
I (9)	Coding Intensity Factor Adjustment	1.063	1.063	1.063	1.063	aggregate DCE calculation designed to make sure there is no change in the normalized risk score for DCEs.
F (10)	Final Coding Adjusted Risk Score (8) / (9)	0.984	0.989	1.038	1.004	Calculated as shown.
(11)	Risk Ratio (10) / (5b)	0.984	1.029	0.989	1.001	Calculated as shown.



RISKSCORE_AD

Direct	Contracting Model Benchmark Repo	rt					
A&D R	isk Score		Baseline	Scenario 1	Scenario 2	Scenario 3	
DXXX		Risk Score Inc >>	1.0000	1.0250	1.0550	0.9900	
Perfor	m CY2022	CIF >>	1.0000	1.0000	1.0000	1.0000	
	n RY2020	Final Risk Score >>		1.0757	1.0757	1.0497	
		Operational Cost >>	NA	\$5.00	\$10.00	(\$6.00)	
		Benchmark >>		\$986.21	\$986.21	\$962.33	
- 11	Jakely	Benchmark Change >>	NA	\$14.26	\$14.26	(\$9.62)	
_	An HMA Company	Net Impact >>		\$ 9.26	\$ 4.26	\$ (3.62)	
		-					
	Claims Aligned	2020	2022 YTD	2022 YTD	2022 YTD	2022 YTD	
1.	Raw Risk Score	1.203	1.254	1.285	1.323	1.241	
2.	Normalization Factor	1.153	1.184	1.184	1.184	1.184	
3.	Normalized Risk Score	1.043	1.059	1.086	1.117	1.048	
4.	PY to RY Capped Beneficiary Ratio		1.000	1.000	1.000	1.000	
5.	PY Risk Score Floor (0.97 X RY norma	alized risk score)	1.012	1.012	1.012	1.012	
6.	PY Risk Score Ceiling (1.03 X RY norm		1.075	1.075	1.075	1.075	
7.	PY Capped Risk Score for Claims Alig		1.059	1.075	1.075	1.048	
8.	CIF		1.000	1.000	1.000	1.000	
9.	PY Benchmark Risk Score for Claims	Aligned	1.059	1.075	1.075	1.048	
<u> </u>	The Bottom and Michigan Scott for Claims	, iiiBiroa	21003	21075	2.075	210 10	
	Voluntary Aligned						
	Newly Voluntarily-Aligned						
10.	PY Raw Risk Score		1.346	1.346	1.346	1.346	
11.	PY Normalization Factor		1.184	1.184	1.184	1.184	
12.	PY Normalized Risk Score		1.171	1.171	1.171	1.171	
	Continuously Voluntarily-Aligned						
13.	PY Raw Risk Score		0.000	0.000	0.000	0.000	
14.	PY Normalization Factor		1.184	1.184	1.184	1.184	
15.	PY Normalized Risk Score		0.000	0.000	0.000	0.000	
16.	PY to RY Capped Beneficiary Ratio		1.000	1.000	1.000	1.000	
17.	PY Risk Score Floor (0.97 X RY norma	alized risk score)	1.012	1.012	1.012	1.012	
18.	PY Risk Score Ceiling (1.03 X RY norm		1.075	1.075	1.075	1.075	
19.	PY Capped Risk Score for Continuous		0.000	0.000	0.000	0.000	
20.	CIF	,,,	1.000	1.000	1.000	1.000	
21.	PY Benchmark Risk Score for Continu	uously Voluntarily-Aligne		0.000	0.000	0.000	
		, ,					
22	Total PY Benchmark Risk Score		190 206	190 206	100 206	190 206	
22.	Claims-Aligned Eligible Months	la mala a	189,206	189,206	189,206	189,206	
23.	Newly Voluntarily-Aligned Eligible M		1,844	1,844	1,844	1,844	
24.	Continuously Voluntarily-Aligned Eli	gible Months	0	0	0	0	
25.	Claims Aligned Risk Score		1.059	1.075	1.075	1.048	
26.	Weighted Average Voluntary Aligne	d Risk Score	1.171	1.171	1.171	1.171	
27.	Weighted Average PY Benchmark Ris	sk Score	1.060	1.076	1.076	1.050	



Provider Level

Provider Scorecard

- Below outlines the provider level benchmarking details
- Targets are set at the overall DCE reported values as found in the quarterly benchmark reports from CMS
- PY = Performance Year

₩ake	lu										Pe	erformance Year	- 2022									
An HMA Company	י,							Ben	chmarking									Expenditures		Shared Savings Reconciliation		
Provider Group	PCP vs Specialist	PBPM Benchmark - PY	Historical Expenditures / Ratebook Adj	Adj Baseline Expenditures (2017 - 2019)	Avg County Rate - Baseline Years (2017 - 2019)	Avg Risk Adjusted Rate - PY	Raw Risk Score - PY	Normalization Factor - PY	Normalized / Capped Risk Score - PY	Normalized Risk Score - Reference Year	Risk Score Cap Factor	Member Months (Annualized) - PY	Member Months - BY 2019	A&D / ESRD Split	Claims Aligned / Regional Only Split	Quality Score	PY Estimated FFS Expenditures	PY Estimated Capitation Expenditures	FFS Expenditures+ Capitation	Benchmark	Expenditures (FFS + Capitation)	Estimated Shared Savings
Provider A	PCP	\$1,195	1.095	\$1,259	\$1,115	\$1,305	1.361	1.118	1.040	0 1.010	1.125	3,693	1,066	97.1%	98.0%	N/A	\$860	\$12	\$860	\$1,171	\$860	\$311
Provider B	Specialist	\$1,254	0.904	\$1,059	\$1,199	\$1,370	1.439	1.118 (1.215	1.246	1.018	28,439	8,582	97.3%	98.0%	N/A	\$1,058	\$12	\$1,058	\$1,229	\$1,058	\$172
Provider C	PCP	\$1,031	0.941	\$1,103	\$1,147	\$1,124	1.115	1.118	1.008	1.039	0.950	20,782	13,209	96.9%	98.0%	N/A	\$882	\$10	\$882	\$1,010	\$882	\$128
Provider D	PCP	\$1,058	0.976	\$1,101	\$1,106	\$1,156	1.219	1.118	1.030	1.003	1.017	39,024	12,635	97.5%	98.0%	N/A	\$853	\$10	\$853	\$1,037	\$853	\$185
Provider E	PCP	\$960	0.967	\$987	\$1,004	\$1,048	1.077	1.118	1.032	1.065	0.897	56,524	45,434	97.2%	97.9%	N/A	\$903	\$9	\$903	\$941	\$903	\$38
Provider F	PCP	\$956	0.908	\$884	993	\$1,045	1.240	1.118	1.111	1.121	0.959	< 10	< 10	97.5%	97.9%	N/A	\$951	\$9	\$951	\$937	\$951	(\$13)
Provider G	PCP	\$839	0.934	\$851	919	917	1.158	1.118	1.030	1.062	0.966	63,727	73,546	97.6%	97.9%	N/A	\$900	\$8	\$900	\$822	\$900	(\$78)
Provider H	Specialist	\$2,387	0.848	\$1,048	\$1,261	\$2,609	2.811	1.118	2.387	2.462	1.012	6,316	3,031	97.3%	96.1%	N/A	\$2,090	\$23	\$2,090	\$2,340	\$2,090	\$250
Provider I	PCP	\$956	0.908	\$884	993	\$1,045	1.240	1.118	1.111	1.121	0.959	< 1 0	< 10	97.5%	97.9%	N/A	\$951	\$9	\$951	\$937	\$951	(\$13)
Provider J	PCP	\$1,374	0.982	\$1,254	\$1,251	\$1,502	1.330	1.118	1.179	1.216	0.969	10,691	9,986	98.0%	97.8%	N/A	\$1,034	\$13	\$1,034	\$1,346	\$1,034	\$312
Provider K	PCP	\$1,211	0.902	\$1,100	\$1,251	\$1,324	1.119	1.118	1.136	1.178	0.847	2,141	5,078	98.0%	96.9%	N/A	\$1,000	\$12	\$1,000	\$1,187	\$1,000	\$186
Provider L	PCP	\$870	0.746	\$748	\$1,040	\$950	1.325	1.118	1.168	1.204	0.975	15,101	19,943	97.4%	98.0%	N/A	\$1,019	\$9	\$1,019	\$853	\$1,019	(\$166)
Provider M	Specialist	\$1,181	0.666	\$844	\$1,284	\$1,290	1.639	1.118	1.435	1.480	0.982	52,514	58,401	97.3%	98.0%	N/A	\$1,254	\$12	\$1,254	\$1,158	\$1,254	(\$96)
ACO/DCE Overall	N/A	\$980	0.908	\$884	\$993	\$1,045	1.240	1.118	1.111	1.121	0.959	1,978,598	522,554	97.5%	97.9%	N/A	\$941	\$10	\$941	\$ 961	\$941	\$20
Target Se	Δι-	40000F Owaral	ACO/DCE Overall	ACO/DCE Overall	ACOIDCE Overall	ACO/DCE Overall	ACOIDCE Overall	A/02	400000F0wara	l ACOIDCE Overall	1.000	/1/02	A/02	A/62	AX61	7.03	A/02	77/02	ACOIDCE Overail	A/02	1,892	A892



WAHOO RSO



PY2023 Opportunity from Recapture and Association

MemID	High_Level _DCG	Reason	Potential_ HCC	Description	HCC_in_ Antecedent	Antecedents	Confidence	Last_Dx	Current_ HCC_in_ DCG	EDS_Weight	Value	Opportunity_ Annualized_ MMs	Include
		Recaptu				ANALGESICS - OPIOID							
		re +		Metastatic Cancer and Acute		(00406012301), HCC8							
552	Cancer	Assn	HCC8	Leukemia	1	(2020 inc)	74.1%	C7931		2.659	1.970	\$17,163.80	1.00
		Recaptu				ANTIANXIETY AGENTS							
		re +		Metastatic Cancer and Acute		(00591024005), HCC8							
415	Cancer	Assn	HCC8	Leukemia	1	(2020 inc)	72.9%	C799		2.659	1.939	\$16,801.22	1.00
		Recaptu											
		re +				HCC27 (2020 inc),							
462	Liver	Assn	HCC27	End-Stage Liver Disease	1	HCC48 (2020 inc)	72.8%	K766		1.101	0.801	\$6,984.11	1.00
		Recaptu											
		re +				HCC9 (2020 inc),							
122	Cancer	Assn	HCC9	Lung and Other Severe Cancers	1	HCC111 (2020 inc)	71.3%	C159		1.024	0.730	\$6,359.18	1.00
		Recaptu											
		re +				HCC9 (2020 inc),							
356	Cancer	Assn	HCC9	Lung and Other Severe Cancers	1	HCC111 (2020 inc)	71.3%	C23		1.024	0.730	\$6,322.10	1.00
		Recaptu											
		re +				HCC9 (2020 inc),							
669	Cancer	Assn	HCC9	Lung and Other Severe Cancers	1	HCC108 (2020 inc)	69.8%	C220		1.024	0.715	\$6,230.63	1.00
		Recaptu				HCC9 (2020 inc),							
		re +				HCC108 (2020 inc),							
684	Cancer	Assn	HCC9	Lung and Other Severe Cancers	1	HCC111 (2020 inc)	73.5%	C3411		1.024	0.753	\$6,228.42	1.00



Scenario

Panel Size	5,000	
Risk Score	1.10	
		Confidence
Closed Gap	547	80%
Closed Gap Risk Score		
Increase	174.0	
Updated Risk Score	1.13	
Increase in Risk Score	3.2%	



For more information, please contact us:

Michael Forster, ASA, MAAA michael.forster@wakely.com

Brad Heywood, ASA, MAAA <u>brad.heywood@wakely.com</u>

